Literature DB >> 10767518

Poor clinical outcome in early stage cervical cancer with human papillomavirus-18 positive lymph nodes.

T Sápy1, Z Hernádi, J Kónya, L Lukácskó.   

Abstract

Epidemiologic and molecular studies have proven that human papillomavirus (HPV) plays an important role in the development of cervical cancer. However, the role of the virus in the progression of the disease, i.e. in the development of lymph node metastasis and in the adverse clinical outcome is poorly understood. We have been using the polymerase chain reaction (PCR) to study the presence and typing of human papillomavirus DNA since 1980 in cervical cancers and pelvic lymph nodes from the same patients. Out of the series of 47 cervical cancer patients we focused on four women (age: 41, 33, 35 and 56 years) in this article. The follow-up of these patients revealed early recurrences of the disease (7, 7, 17, 22 months) with very short survival (9, 10, 21, 24 months). Although we detected HPV-18 positivity both in the cervical tumors and in the regional lymph nodes too in all four cases, lymph nodes were negative by routine hystology in case of the three young patients (21, 33, 35 years of age). Our observations suggest that HPV type 18 positive cervical cancer patients, despite negative histological findings in the lymph nodes should be consider as a subpopulation for poor outcome especially in the young age group (p=0,022, Fisher's exact test).

Entities:  

Mesh:

Year:  2000        PMID: 10767518     DOI: 10.1016/s0301-2115(99)00226-2

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  1 in total

Review 1.  Usefulness, methods and rationale of lymph nodes HPV-DNA investigation in estimating risk of early stage cervical cancer recurrence: a systematic literature review.

Authors:  Marco Noventa; Emanuele Ancona; Erich Cosmi; Carlo Saccardi; Pietro Litta; Donato D'Antona; Giovanni Battista Nardelli; Salvatore Gizzo
Journal:  Clin Exp Metastasis       Date:  2014-07-20       Impact factor: 5.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.